Adenoid Cystic Carcinoma of Breast: A Review of Molecular Markers to Elucidate its Cancer Biology

Allan L. Hilario*, MD, MHA, MSc, John Robert C. Medina**, MD, MHS, Catherine Lynn T. Silao***, MD, PhD

*Department of Biochemistry and Molecular Biology, College of Medicine, University of the Philippines Manila, Manila City, Philippines
**Department of Epidemiology and Biostatistics, College of Public Health, University of the Philippines Manila, Manila City, Philippines
***Department of Pediatrics, College of Medicine, University of the Philippines Manila, Manila City, Philippines
****Institute of Human Genetics, National Institutes of Health, University of the Philippines Manila, Manila City, Philippines

*Corresponding Author
Allan L Hilario, MD, MHA, MSc
Department of Biochemistry and Molecular Biology, College of Medicine, University of the Philippines Manila, Manila City, Philippines
Tel/Fax: +63285264197
Email: alhilario@up.edu.ph

Abstract
Background: Adenoid cystic carcinoma (ACC) of breast is a rare type of breast cancer, which belongs to the triple-negative breast cancer associated with aggressive behavior and poor prognosis. Despite being classified as triple-negative breast cancer, ACC of breast is an indolent subtype with good biological behavior, less aggressive course, good response to treatment and clinical outcomes. It has generally a good overall survival with no propensity for metastasis. Thus, a correct diagnosis could be of great importance for providing proper and adequate treatment.

Method: Published literature was reviewed to determine differentially expressed genes that could be used as biomarkers for this disease and to elucidate the biology and carcinogenesis of ACC of breast according to this genetic profile.

Results: Several genes were differentially expressed and were found to belong to a wide range of biological processes. The most prevalent genetic alteration is a gene translocation that produces the MYB-NF1B fusion gene and the overexpression of MYB, which initiates tumorigenesis. This crucial genetic aberration is the hallmark of adenoid cystic carcinoma. The rest of the genes are involved in cell proliferation, apoptosis, stable epithelial phenotype, tumor suppression, and keeping an intact basement membrane, evasion of epithelial-mesenchymal transition, and prevention of metastasis.

Conclusion: This gene expression is responsible for various biological processes that reflect the biology of ACC of breast with an indolent course and good clinical outcomes. This genetic profile impacts biomarker research and could be used to refine patient diagnosis and selection for appropriate and less aggressive treatment options.

Keywords: Adenoid cystic carcinoma, Breast, Biomarkers, Review
Introduction

Adenoid cystic carcinoma (ACC) is a non-heritable cancer with varied clinical courses and prognoses depending on the organ of origin. Its treatment depends on a myriad of factors with different responses to surgery, radiotherapy, and chemotherapy. The etiology remains unknown, but a common genetic alteration seems to initiate tumorigenesis. It is an uncommon cancer of exocrine glandular origin, which could be found in various parts of the body. It is found more commonly in the salivary glands, accounting for about 10-25% of all salivary gland malignancies. This form of cancer makes ACC the second most prevalent malignancy of both major and minor salivary glands.\(^{1}\) It could be detected in other parts of the body, such as head and neck, lacrimal glands, auditory tract, upper respiratory tract, trachea, lungs, breast, skin, gastrointestinal tract, prostate, and gynecological tract. Genetically, ACC is similar throughout the body with minor mosaicism. It has a histologic characteristic of tangled cylinders composed of a hyaline stroma with intertwined epithelial and myoepithelial cells. Hence, it is also known as “cylindroma” as coined by Billroth. Cylindroma later on gained infamy and was changed to its present term of ACC for the salivary gland by Ewing in 1919 and for breast by Geschickter in 1945. Currently, it has four histological architectural patterns, namely cribriform, tubular, trabecular, and solid for primary and metastatic ACC.\(^{2}\)

Despite being a rare malignancy, molecular profiling of ACC has been the focus of intensive research over the recent years. Most ACC found in various sites of the body have similar genetic characteristics with unique molecular drivers from an indolent type to a more aggressive form. Elucidating ACC carcinogenesis has evolved with advances in genetic testing, in other words, genetic studies using immunohistochemistry (IHC)\(^{3}\), fluorescence in-situ hybridization (FISH)\(^{4}\), and microarray assay.\(^{5-7}\) Tumorigenesis of ACC starts with the activation of the proto-oncogene, \textit{MYB}, and the loss of function of a transcription factor, \textit{NFIB}, due to chromosomal translocation involving chromosomes 6 and 9. This translocation results in gene fusion characterized as \((t(6:9) \ (q22-23;p23-24))\) and a deletion of the chromosomal band 6q at chromosome 6 activating other proto-oncogenes, such as \textit{c-ros}, \textit{c-syn}, and \textit{c-myb}. These genetic alterations are common to all the ACC in the body and lead to the evasion of apoptosis, dysregulation of cell cycle control, and uncontrolled cell growth.\(^{8}\)

Gene translocation, as a driver of carcinogenesis, appears to be widespread in several cancers not only in ACC. The activation of \textit{MYB-NFIB} and \textit{MYBL1-NFIB} fusion oncogenes initiates the role of \textit{MYB} transcription factors in the sequence of events, which leads to ACC carcinogenesis. ACC of the salivary gland (ACCs) is one of the numerous ACC types, which appears to be initiated this way. ACC is the most common malignancy of minor salivary glands\(^{9}\) and is the second prevalent malignancy of the parotid and major salivary glands.\(^{10, 11}\) ACC of head and neck, including salivary glands, is considered as one of the most destructive cancers leading to significant facial disfigurement and a biologically erratic malignant course. Clinically, it is characterized as a slow growing type of cancer, yet with disparate tumor boundary and poor prognosis, which is aggressive and is more likely to recur in the primary site and metastasize. This is commonly seen in ACC of salivary gland origin.\(^{12}\) Unlike its anatomical cousin, ACC of breast (ACCb) with genetic similarity to ACCs, has the opposite clinical and biological behavior.\(^{13}\)

ACCb accounts for less than 1% of all breast cancer types in the world. ACC of breast belongs to the triple-negative breast cancer (TNBC) which does not
express the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). However, ACCb is a very distinct subtype of TNBC. TNBC is quite similar to ACCs in terms of prognosis, aggressiveness, response to treatment, clinical outcomes, and survival. Among the histologic types of TNBC, ACCb has a favorable course with a good prognosis and an overall survival rate ranging from 85-100%. Even with few cases of recurrence to the primary site and metastasis to some organs, the general clinical outlook following the treatment remains very good. Hence, it is imperative to identify specific and distinct molecular signatures of this histologic type of TNBC to improve diagnosis, properly select patients, provide appropriate targeted therapeutic strategies, and prevent these patients with ACCb from undergoing destructive surgeries and aggressive adjuvant therapy as advised for those with TNBC in general. This literature review aimed to determine the molecular markers of ACC of breast and elucidate its cancer biology and carcinogenesis based on the interplay of these differentially expressed genes published in literature.

Materials and Methods
A literature search was conducted using the mesh words “adenoid cystic carcinoma”, “breast”, and “biomarkers” in PubMed for the articles published from 1990 to 2019. The search was done in 18 February 2020. Each article was evaluated for inclusion in this narrative review. The articles were included according to the following criteria: 1) studies that reported ACCb with biomarkers or molecular testing applying various methods, such as IHC, FISH, and microarray-based assays; 2) studies derived from molecular data sets of human ACCb mined from publicly available repositories; 3) review articles, case reports, case series, and studies about ACCb with molecular profiles employing various techniques, such as IHC, FISH, and PCR-based assays. The exclusion criteria included: 1) studies on ACC of other sites; 2) studies not written in English; 3) studies done using animal models and cell lines. The guidelines recommended by Preferred Reporting Item for Systematic Reviews and Meta-Analyses (PRISMA) were followed in this review.18

Results
After performing a PubMed search using the mesh words “adenoid cystic carcinoma”, “breast”, and “biomarkers”, 217 articles were recognized. After evaluating each of these articles based on the inclusion and exclusion criteria, 71 articles were chosen. Each article was reviewed according to the purpose of this study. After the initial review, 49 articles were chosen and downloaded. Each full-text article was reviewed and checked if molecular profile was reported. Finally, eight articles were employed in this work (Figure 1). All the differentially expressed genes were tabulated (Table 1). Several genes were identified, which belonged to a wide range of biological processes.

Discussion
Summary of evidence and limitation
The generated gene set from the included studies in this systematic review showed a robust genetic profile which could be utilized for the basis of the elucidation of its cancer biology as discussed in this review. The findings of this review were based on the eight studies included, in which adenoid cystic breast disease was not expected to be a common triple-negative breast cancer type.

General considerations in clinical use of biomarker research for breast cancer
In general, the mainstay of breast cancer management is surgery either by breast-conservation surgery or simple to modified radical mastectomy with breast reconstruction, followed by adjuvant chemotherapy, adjuvant radiation
therapy, and various targeted therapies. Targeted therapies include hormonal therapy for ER+ and PR+ breast cancer types and immunotherapy with trastuzumab for HER2+ breast cancer types. The standard biomarkers used include ER, PR, HER2, and Ki67, which are tested by IHC and FISH. The use of microarray-based biomarkers has not indicated any significant clinical uses or evidence-based guidelines, as recommended by various organizations, like the American Society of Clinical Oncology (ASCO), National Comprehensive Cancer Network (NCCN), and the St. Gallen Group (SGG). Breast cancer susceptibility genes, BRCA 1 and 2, are also used in the evaluation of the hereditary form of breast cancer. These few biomarkers are currently the ones being utilized in the prognostication and treatment planning and targeted therapeutics despite significant strides in breast cancer biomarker research employing IHC, FISH, and micro-array assay techniques for molecular profiling.

The clinical use of biomarkers for breast cancer is quite limited. However, the number of breast cancers-associated tumor biomarkers and its various types and subtypes has exploded due to the robust research on breast cancer biomarkers. Breast cancer biomarkers comprise a wide range of biomolecules from nucleic acids to proteins and metabolites. The biomarkers are generally used to provide specific molecular categorization of breast cancers in types and subtypes with distinct prognostic features and treatment response evaluation and targeted therapeutics. Nonetheless, proteomic biomarkers are commonly studied and used for targeted therapies and clinical diagnostic assays owing to their utility in diagnosis and therapy via various standard existing molecular platforms. This also enables the characterization of breast cancer into molecular types and subtypes associated with particular clinical outcomes, making the use of these biomarkers highly important clinically for biological classification, molecular typing and subtyping, prognostication, and targeted therapeutics.

An important breast cancer type, which has been extensively studied regarding to the elucidation of biomarkers and molecular profiling, is the triple-negative breast cancer (TNBC). Advances in molecular profiling has led to the molecular subtyping of TNBC to molecularly distinct subtypes with different clinical outcomes and prognosis. TNBC is presently subtyped into the following: 1) basal-like, 2) immunomodulatory, 3) luminal androgen receptor, 4) mesenchymal, and 5) mesenchymal stem-like. These subtypes have different clinical and molecular profiles associated with different prognosis and response to the available treatments. All these subtypes are characterized by aggressive behavior, poor prognosis, invariable treatment response, and limited treatment options in addition to high regional and distant metastasis, recurrence, and mortality, except for one, the ACCb, which is more comparable to the basal-like molecular sub-type based on genomic and transcriptome analyses. Thus, the use of biomarkers to clinically identify ACCb patients among TNBC patients may benefit from a more conservative treatment option despite being classified as TNBC, which may be approached by most surgeons and oncologists aggressively in their treatment planning.

**Adenoid cystic carcinoma of breast (ACCb) and molecular subtyping of TNBC**

ACC of breast belongs to a very heterogenous breast cancer type, the triple-negative breast cancer, and is associated with diverse molecular signals and various molecular subtypes. Several studies on genomic and molecular profiling have reported various subtyping of TNBC. These several subtyping of TNBC have proven that TNBC is a far highly
heterogenous both in its genotype and phenotype. Molecular heterogeneity has resulted in further TNBC subtypes with different biological characteristics and clinical outcomes. Despite the fact that TNBC consists of several molecular subtypes, breast cancer phenotype correlates well with genotype, which is further defined and clarified in ACCb. Specific genotype-phenotype correlations are based on a single chromosomal aberration involving the reciprocal translocation between the long arm of chromosome 6 in MYB and the short arm of chromosome 9 within nuclear factor I/B (NF1B). This chromosomal translocation is responsible for the formation of the MYB-NF1B fusion gene that results in the overexpression of MYB, a transcription factor, and carcinogenesis of ACC. This chromosomal aberration is common to all ACC found in different body parts.46

Breast cancer diagnosis has been based broadly on standard histopathologic techniques with the aid of certain clinically accepted biomarkers which are most commonly detected using IHC and FISH on formalin-fixed and paraffin-embedded tumor tissues. However, the diagnostic use of molecular typing based on microarray assays of breast cancer in general and TNBC in particular have not reached significant clinical use by the medical community because of the presence of several classification models for molecular typing and the absence of concurrence among these different molecular models. The limited use of molecular typing remains in the purview of scientific research and has not crossed over to clinical application despite clear evidence indicating that molecular typing of TNBC and special types of breast cancers shows distinct molecular signatures that could be conducive to disease prognostication and treatment planning employing standard treatment options and targeted therapeutics. Much has to be done to make high throughput technologies in molecular subtyping to gain wide acceptance in clinical use. One reason behind such resistance may be the increasing complexity and variability of molecular subtypes reported in the literature with no definitive application for clinical use. Several clinicians question the use of molecular taxonomy instead of the standard histopathologic labeling of various breast cancer types and subtypes despite evidence implying that TNBC subtypes have clearly unique molecular signatures with significant clinical implications.47, 48

Biomarkers of breast adenoid cystic carcinoma

ACCb most likely corresponds to the basal-like subtype of TNBC which is distinctly different from basal-like subtypes of breast cancer. It belongs to the largest breast cancer histopathologic type, which is the invasive ductal carcinoma or invasive carcinoma of no special type based on recent World Health Organization disease classification.49 ACCb has a morphological and histological feature and distinct genetic signature associated with negative regulation of genes responsible for cell migration, proliferation, and immune response. ACCb is a unique special type of breast cancer with good prognosis classified within a very aggressive breast cancer type, which is TNBC.50 Several reports have confirmed the same findings including other indolent special types of breast cancers.51

The biomarkers of ACCb in this review showed a similar expression of biomarkers characterizing the basal-like subtype of TNBC and special type of breast cancer. This gene expression profile includes the negative expression of ER, PR, and HER2 and the positive expression of MYB,19, 24 E-cadherin,22 P-cadherin,22 keratin 5, keratin 7, keratin 17,21,22, 25 EGFR,21, 22 fibroblast growth factor receptor (FGFR),26 V-Set Domain Containing T Cell Activation Inhibitor 1 (VTCN1),26 c-KIT,21, 24, Ki-67,23 SMA,20,
In its biology, the cancer stem cell hypothesis and the subclonal evolution of the cancer cells may result in ACCb pathogenesis, which can push it to undergo transformation to high-grade TNBC explaining the few case reports of metastasis associated with ACCb. The same MYB-NF1B fusion gene and a clonal NOTCH1 mutation play roles in the dysregulation of NOTCH1 signaling pathway and contribute to the ACCb pathogenesis and aggressiveness. Although these are just few case reports of metastases of ACCb, the general outlook of ACCb is still less aggressive with less predisposition for lymphatic and hematogenous spread.

**Biology of ACCb**

The indolent biological behavior of ACCb may be attributed to its genetic profile. Even though such correlation may not be well-understood and well-demonstrated using specific cell line studies, the genetic characteristics of ACCb play a significant role in its biology and carcinogenesis. Genetically, ACCb has a stable genome with low genetic instability and single copy number aberration. It could be attributed to its low mutation rate when compared with its salivary counterpart with a high mutation rate, opposite biological behavior, and poor prognosis. The absence of a p53 gene mutation in ACCb may also be responsible for such biological behavior. In contrast to most TNBC, where ACCb belongs as a breast cancer type, mutations in the p53 gene are widespread in TNBC, which could explain the aggressive behavior and generally poorer prognosis of TNBC despite the loss of function of p63 in ACCb as reported in this study. The p63 gene clearly plays a minor role in apoptosis and ACCb cell proliferation as shown in Figure 3, which explains the good prognosis and clinical outcomes of ACCb when compared with TNBC.

24 CRYAB, 25 ID4, 25 and loss of function of p63. 21, 22 These differentially expressed genes are responsible for the biology of ACCb from the initiation of tumor formation, carcinogenesis, and clinical features that favors good prognosis with less potential for metastasis and good response for chemotherapy and indolent clinical course.

**Tumorigenesis and disease progression of ACCb**

The underpinning driver of tumorigenesis of ACC is the MYB-NF1B gene fusion not only in breast, but also in all ACC of different parts of the body. The mechanism is similar in different ACCs of the body. The overexpression of MYB, a transcription factor, causes the basal and myoepithelial cell of the mammary glandular unit to undergo uncontrolled cell proliferation and evasion of apoptosis. The resulting clonal progression of these epithelial cells lining the ductal and terminal acini of the mammary glands establishes the tumor. The acquired multiple chromosomal mutation results in malignant degeneration for ACCb. This carcinogenesis mimics the arrest of the epithelial developmental stage where the luminal progenitor and myoepithelial progenitor cells of the mammary glandular epithelium fail to normally differentiate and develop to basal cell and myoepithelial cell, respectively, underlining the ductal and lobular acini of the mammary gland unit due to BRAC 1 mutation and dysfunctional BRAC 1 pathway. BRCA 1-deficient cells and the interplay with dysregulated BRAC 1 pathway result in the mammary epithelial developmental arrest leading to a basal-like subtype of TNBC and also reminiscence of the evolution of ACCb as shown in figure 2. 25

Although ACCb is not biologically aggressive, this particular type of breast cancer and a subtype of TNBC have low risk of nodal and systemic metastasis. However, there are several case reports of ACCb with documented metastasis to the brain, lungs, kidneys, the axillary lymph nodes, and the bone even though ACCb rarely metastasizes regionally and systemically. In addition, the cancer stem cell hypothesis and the subclonal evolution of the cancer cells may result in ACCb pathogenesis, which can push it to undergo transformation to high-grade TNBC explaining the few case reports of metastasis associated with ACCb. The same MYB-NF1B fusion gene and a clonal NOTCH1 mutation play roles in the dysregulation of NOTCH1 signaling pathway and contribute to the ACCb pathogenesis and aggressiveness. Although these are just few case reports of metastases of ACCb, the general outlook of ACCb is still less aggressive with less predisposition for lymphatic and hematogenous spread.
The overexpression of significant cytokeratin, such as Keratin 5, 7, and 17, E-cadherin, and P-cadherin, promotes the epithelial characteristics of ACCb. These proteins are responsible for cell structural integrity and tight junctions between epithelial cell lining of the ductal and lobular acini of the mammary glandular unit. Despite the overexpression of SMA and FGFR proteins, which clearly provides mesenchymal features, the balance of epithelial and mesenchymal characteristics of ACCb ensures that epithelial-mesenchymal transition (EMT) does not occur. The initiation of EMT is a strong driver for metastasis where mammary epithelial cells lose their immotile features and change to a mobile feature of mesenchymal cells, like fibroblasts. Furthermore, ACCb has been shown to mutate the ZEB1, twist, and snail genes, which are strong drivers of EMT as shown in Figure 4. The loss of functions of these EMT drivers further prevents ACCb from undergoing metastasis through EMT.

The overexpression of various keratins ensures cytoskeletal integrity of the myoepithelial cells, the structural integrity of the basement membrane and evasion of EMT results in a highly stable tumor cell population despite the influence of SMA and FGFR for a more mesenchymal feature. The terminal lobular acini of the mammary glandular unit is lined by epithelial cells encircled by myoepithelial cells with the ability to contract. These cellular architecture and units sit on the basement membrane. This site is believed to be the origin of most breast cancers. The characteristic gene expression of ACCb, which produces these various protein products, creates a tumor microenvironment where the transformed epithelial and myoepithelial cells to cancer cells are allowed to remain in a stable tumor population. The sustained epithelial features prevent EMT while the intact basement membrane restricts the tumor growth well contained in the terminal lobular acini of the mammary glandular unit. These mechanisms prevent metastasis whereas the balance of the countering processes of cell proliferation and tumor suppression and apoptosis may contribute to its indolent behavior.

**Clinical implications of biomarkers in ACCb**

The establishment of a distinct genetic profile or biomarkers for ACCb allows a definitive diagnosis of ACCb beyond a histopathologic diagnosis, which could be utilized to correctly identify patients with ACCb despite being included in triple-negative breast cancer. This is important since ACCb and TNBC have different prognosis, clinical outcomes, and responses to conventional breast cancer treatment. The clinical practice guidelines in the diagnosis and treatment of breast cancer are conventionally based on different clinical and histopathologic variables, like tumor size, histologic grade, stage and status of a few biomarkers, such as ER, PR, HER2, and Ki-67. Being classified as TNBC, the treatment of ACCb is already limited to surgery, chemotherapy, and radiotherapy. Hormonal and anti-HER2/neu therapies are no longer applicable. ACCb may be aggressively treated for being considered as TNBC in spite of having a good prognosis and good response to treatment. ACCb is a rare type of breast cancer and the available treatments are not subjected to randomized clinical trials unlike the most prevalent types of breast cancer, such invasive ductal and lobular carcinomas. Currently, treatment options for ACCb, such as surgery, chemotherapy, and radiotherapy, are based on certain large population-based studies, case reports, and case series. Thus, identification of unique biomarkers for ACCb will certainly benefit patients in terms of treatment.

The identification of a unique genetic signature might also contribute to targeted therapy. Presently, there are no targeted therapies for ACCb in clinical use. Meanwhile, research on molecular
profiling of ACCb may lead to such targeted therapy. Some of the established molecular signals in this review are currently being investigated in pre-clinical and clinical studies. MYB has been targeted for anti-tumor therapy for leukemias and solid tumors, including breast cancer. However, anti-MYB therapies, which include DNA vaccine, inhibition using RNA interference and silencing, and small molecule compounds with potential inhibitory effect, have been focused on in various pre-clinical and clinical studies. Another biomarker with targeted therapeutic potential is the c-KIT, a receptor tyrosine kinase (RTK). The use of RTK inhibitors is considered complementary with other anti-cancer modalities and not as a single therapy; it has not been used specifically for ACCb. However, various RTK inhibitors are in different levels of clinical trials for TNBC and breast cancer in combination with other cancer treatment modalities. The use of anti-EGFR drugs such as the dual tyrosine kinase inhibitor, lapatinib, which targets both HER2/neu and EGFR has been approved for clinical used in ER+, HER2+, and EGFR+ breast cancer but not in ACCb. Another possible target is the FGFR with the use of inhibitors for the tyrosine kinase pathways. Several FGFR inhibitors are in various phases of clinical trials and in combination with other cancer modalities. These trials are for various cancers, including breast cancer. Lastly, the use of Ki-67 protein as an index of cell proliferation has been established as a diagnostic and prognostic tool in breast cancer. Moreover, ER, PR, HER2, BRCA 1/2, and Ki-67 are taken into consideration in the guidelines by the St. Gallen Group in the evidence-based clinical practice guidelines for breast cancer including ACCb. Conclusion

ACCb is an indolent and rare special type of breast cancer with a different clinical course and biology from triple-negative breast cancer. Being less aggressive, it has good clinical outcomes, good prognosis, and good response to treatment and rarely undergoes nodal and distant metastasis unlike its salivary counterpart. Nevertheless, like all ACCs in the body, it is triggered by translocation of chromosomes 6 and 9 leading to oncogenic activation of MYB-NF1B fusion gene and overexpression of MYB transcription factor. This cancer has distinct genetic signatures, which affect cell proliferation, tumor suppression, apoptosis, evasion of EMT, and ensure integrity of the basement membrane. As a complement to histopathologic diagnosis, this genetic profile can be used in order to obtain a more accurate diagnosis. These genetic signatures and their protein products influence the biology and carcinogenesis of ACCb with good clinical outcomes and good prognosis.

Acknowledgments

This work was part of the TNBC Philippine Research Project© approved by the University of the Philippines Manila Research Ethics Board (UPMREB Approval No. 2020-070-01) and was registered in the Research Grants and Administration Office (RGAO) of the UPM-NIH (Reg. no. 2019-1131).

Funding Statement

This work was part of the TNBC Philippine Research Project© which was funded by the NIH Faculty Research Grant of the National Institutes of Health, University of the Philippines Manila (UPM-NIH).

Conflicts of Interest

None declared.
References


Table 1. Differentially expressed genes in adenoid cystic carcinoma of breast from the literature

<table>
<thead>
<tr>
<th>Gene</th>
<th>Gene Name</th>
<th>Biological Process</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>MYB</td>
<td>MYB proto-oncogene transcription factor</td>
<td>HTH DNA binding domain as transcription regulation</td>
<td>19, 24</td>
</tr>
<tr>
<td>CK7</td>
<td>Keratin 7</td>
<td>Cytoskeleton of epithelium</td>
<td>20</td>
</tr>
<tr>
<td>CK 5/6</td>
<td>Keratin 5</td>
<td>Cytoskeleton of epithelium</td>
<td>20, 21, 22, 25</td>
</tr>
<tr>
<td>CK17</td>
<td>Keratin 17</td>
<td>Cytoskeleton of epithelium</td>
<td>20, 25</td>
</tr>
<tr>
<td>c-KIT</td>
<td>Receptor tyrosine kinase receptor</td>
<td>Cytoskeleton of epithelium</td>
<td>21</td>
</tr>
<tr>
<td>EGFR</td>
<td>Epidermal growth factor</td>
<td>Cell proliferation</td>
<td>21, 25</td>
</tr>
<tr>
<td>p63</td>
<td>Tumor protein p63</td>
<td>Tumor suppression</td>
<td>21, 22</td>
</tr>
<tr>
<td>P-cadherin</td>
<td>Cadherin 3</td>
<td>Cell-cell adhesion</td>
<td>22</td>
</tr>
<tr>
<td>E-cadherin</td>
<td>Cadherin 1</td>
<td>Cell-cell adhesion</td>
<td>22</td>
</tr>
<tr>
<td>Ki-67</td>
<td>Marker of proliferation Ki-67</td>
<td>Cell proliferation</td>
<td>23</td>
</tr>
<tr>
<td>SMA</td>
<td>Actin alpha 2, smooth muscle</td>
<td>Cell motility</td>
<td>20, 24</td>
</tr>
<tr>
<td>CRYAB</td>
<td>Alpha crystalline B chain</td>
<td>Heat-shock protein, inhibits apoptosis</td>
<td>25</td>
</tr>
<tr>
<td>ID4</td>
<td>Transcription inhibitory protein</td>
<td>Cell proliferation</td>
<td>25</td>
</tr>
<tr>
<td>VTCN1</td>
<td>V-set domain containing T-cell activation inhibitor 1</td>
<td>Tumor progression</td>
<td>26</td>
</tr>
<tr>
<td>FGFR</td>
<td>Fibroblast growth factor receptor</td>
<td>Fibroblast proliferation and differentiation</td>
<td>26</td>
</tr>
</tbody>
</table>

Figure 1. The flowchart used in the selection of the studies with genetic profile of adenoid cystic carcinoma of breast in the generation of gene set.

ACC: Adenoid cystic carcinoma; ACCb: Adenoid cystic carcinoma of the breast.
Figure 2. This figure shows the genetic events that initiate tumorigenesis of adenoid cystic carcinoma of breast.

ACCb: Adenoid cystic carcinoma of the breast; BRCA1: Breast cancer gene 1; MYB-NF1B: Myeloblastosis-Nuclear Factor 1 B-type.
Figure 3. This figure shows the genetic interplay that sustains the tumor population of adenoid cystic carcinoma of breast.

ACCb: Adenoid cystic carcinoma of the breast; p63: Tumor suppressor gene 63; Ki-67: a marker of cell proliferation where Ki came from the place of discovery (Kiel, Germany) and clone number; e-KIT: cellular-Kinase tyrosine; EGFR: Epidermal growth factor receptor; VTCN1: V-set domain containing T-cell activation inhibitor 1; FGFR: Fibroblast growth factor receptor; CRYAB: Alpha crystalline B chain; ID4: Inhibition of DNA-Binding 4.
Figure 4. The mechanism of preventing metastasis in adenoid cystic carcinoma of breast is mainly based on the molecular regulation of epithelial-mesenchymal transition. ZEB1: Zinc finger E-box-binding homeobox 1; EMT: Epithelial-mesenchymal transition